Europe may accelerate review of RevMed cancer drug

Europe's drug regulators are considering fast-tracking RevMed's cancer drug, reflecting a push for quicker access to new treatments. This potential acceleration comes alongside new GLP-1 data from Kailera raising concerns, and FDA clearance for Vera's autoimmune therapy. The move highlights evolving regulatory landscapes and a keen eye on pipeline innovations in biotech.